Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University Medical Center Goettingen

- PMLiVE

NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer

The AI tool is expected to help doctors plan each patient’s radiotherapy treatment

- PMLiVE

New blood test could one day be used to diagnose Parkinson’s disease

The discovery could potentially lead to the development of a definitive diagnostic test

- PMLiVE

International survey reveals varying effects of oral medicines for Parkinson’s

More than 65% of respondents reported variations in the effects of taking oral medications

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

- PMLiVE

Study shows AI scans could detect Parkinson’s years before clinical presentation

OCT scans could be used by the NHS for the diagnosis of neurodegenerative diseases

- PMLiVE

NICE recommends AI technologies for radiotherapy treatment planning

AI technology could provide the NHS with significant time and cost benefits

- PMLiVE

AI-supported mammography screening shows promise in breast cancer detection

The AI-supported screening tool detected cancer in 244 people in the study

AI in healthcare communication, today and tomorrow.

Advances in AI technology have meant that agencies can now provide genuine utility to healthcare communications.

Page & Page and Partners

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

- PMLiVE

FDA declines to approve Amneal Pharmaceuticals’ Parkinson’s disease treatment

The regulator said the safety for one of the drug's ingredients had not been adequately established

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links